High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: Qualitative insights from a phase i trial of intermittent and daily PrEP in at-risk populations in Kenya

AIDS and Behavior

Volumn 17, Issue 6, 2013, Pages 2162-2172

  Van Der Elst, Elisabeth Maria ^a   Mbogua, Judie ^b   Operario, Don ^c   Mutua, Gaudensia ^d   Kuo, Caroline ^c   Mugo, Peter ^a   Kanungi, Jennifer ^a   Singh, Sagri ^b   Haberer, Jessica ^e   Priddy, Frances ^b   Sanders, Eduard Joachim ^a,f  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c BROWN UNIVERSITY   (United States)

^d Kenya AIDS Vaccine Initiative   (Kenya)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adherence; HIV pre exposure prophylaxis; Kenya; Men who have sex with men; PrEP

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ORGANOPHOSPHORUS COMPOUND;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MALE; MALE HOMOSEXUALITY; MEDICATION COMPLIANCE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROSTITUTION; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SOCIAL PSYCHOLOGY; STATISTICS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; KENYA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; SEX WORKERS; STEREOTYPING; YOUNG ADULT;

EID: 84879027335     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0317-8     Document Type: Article

References (23)

1. Garcia-Lerma J, Otten R, Qari S, Jackson E, Cong M, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):28.
2. García-Lerma J, Cong M, Mitchell J, Youngpairoj A, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14.
3. Denton P, Estes J, Sun Z, Othieno F, Wei B, Wege A, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16.
4. Neff C, Ndolo T, Tandon A, Habu Y, Akkina R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One. 2010;5(12):e15257.
5. Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010;363(27):2587-99.
6. Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa. University of Washington International Clinical Research Center, Partners in PrEP Study; 2011 [cited 2011 July 30, 2011]; Available from: http://depts.washington.edu/uwicrc/ research/studies/files/PrEP-PressRelease-UW-13Jul2011.pdf. Accessed 19 Sept 2012.
7. CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. 2011 [cited 2011 July 30, 2011]; Available from: http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html. Accessed 19 Sept 2012.
8. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54:548-55.
9. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77-83.
10. Galea J, Kinsler J, Salazar X, Lee S, Giron M, Sayles J, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256-62.
11. Dunkle K, Wingood G, Camp C, DiClemente R. Intention to use pre-exposure prophylaxis among African-American and white women in the United States: results from a national telephone survey. XVII International AIDS Conference; Mexico City, Mexico; 2008.
12. Schneider J, Dandona R, Pasupneti S, Lakshmi V, Liao C, Yeldandi V, et al. Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers. PLoS One. 2010;5(7):e11922.
13. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, Safren S, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463-8.
14. Mutua G, Sanders E, Mugo P, Anzala O, Haberer J, Bangsberg D, et al. A randomized trial of intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men: safety and Adherence. PLoS One. 2012;7:e33103.
15. Smith A, Muhaari A, Agwanda C, Kowuo D, van der Elst EM, Davies A. Female clients and partners of MSM sex workers in Mombasa. Paper presented at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Mombasa: CROI; 2010.
16. Ritchie J, Spencer L, editors. Qualitative data analysis for applied policy research. London: Routledge; 1994.
17. Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr. 2010;55(1):8-13.
18. Remien RH, Stirratt JJ, Dolezal C, Dognin JS, Wagner GJ, Carballo-Dieguez A, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS. 2005;19:807-14.
19. Paxton LA, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: what if it works? Lancet. 2007;370:89-93.
20. Nozaki I, Dube C, Kakimoto K, Yamada N, Simpungwe JB. Social factors affecting ART adherence in rural settings in Zambia. AIDS Care. 2011;10:1-8.
21. Mansergh G, Koblin B, Colfax G, McKirnan D, Flores S, Hudson S. Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among US men who have sex with men. J Acquir Immune Defic Syndr. 2010;55(2):e14-6.
22. Larson E, Lin SX, Gomez-Duarte C. Antibiotic use in Hispanic households, New York City. Emerg Infect Dis. 2003;9:1096-102.
23. Petersen EE, Rasmussen SA, Daniel KL, Yazdy MM, Honein MA. Prescription medication borrowing and sharing among women of reproductive age. J Womens Health. 2008;17(7):1073-80.